Anorexiant Market Status and Prospects 2022 to 2032 | By Janssen Ortho, Novo Nordisk, Epic Pharma, MOVA Pharmaceuticals

In 2022, the global Anorexiant market sales was held at around US$ 1 billion. The Anorexiants market is expected to grow at a CAGR of 5.3% over the forecast period. The increased prevalence of obesity can be ascribed to the increase in growth. According to a CDC data issued in May 2022, the United States increased from 35% to 41.9% from 1990 to 2000 to 2017 to 2020.

According to WHO, 39 million children under the age of five and over 600 million people are obese in 2021. This aspect is driving healthcare spending, which is projected to drive demand for Anorexiants in the coming years.

Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9574

Anorexiants: Market Insights

Obesity is treated with Anorexiants. Anorexiants inhibit appetite control while increasing the individual’s basal metabolic rate. Anorexiants also increase cellular glucose uptake while decreasing dietary fat absorption.

According to the World Health Organization’s statistics report, more than 1.9 billion persons aged 18 and older were judged to be overweight in 2016, with 650 million adults being obese. Furthermore, an estimated 41 million children under the age of five were reported to be obese in 2016.

Anorexiants: Market Dynamics

Anorexiants are predicted to increase significantly in the market due to their usefulness in the treatment of obesity. Anorexiants can help with weight loss by lowering calorie intake, especially in patients with a BMI of 30 or higher.

Because Anorexiants are used to treat obesity, the market is likely to expand. Anorexics, on the other hand, have some limitations. Anorexiants may cause a variety of negative effects such as sleeplessness, increased blood pressure, restlessness, drug dependence, and so on, which may have an impact on the Anorexiants market. Furthermore, long-term use of Anorexiants leads to drug addiction, which can lead to health problems later in life.

For critical insights on this market, request to ask an expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-9574

Anorexiants Market: Overview

Because of the increased prevalence of obesity worldwide, the Anorexiants industry is likely to generate significant revenue in the next years. Some of the Anorexiants used to treat obesity include orlistat, lorcaserinER, liraglutide, naltrexone/bupropion ER, lorcaserin, and phentermine/topiramate ER. Many medications have been licenced by the FDA for the treatment of obesity, therefore the Anorexiants market is expected to rise in the next years.

According to the Centres for Disease Control and Prevention, the prevalence of obesity in the United States is projected to be 39.8%, impacting 93.3 million individuals. As the prevalence and incidence of weight gain and obesity rise, the global Anorexiants market will expand.

Anorexiants Market: Region-wise Outlook

The global Anorexiants market is divided into seven key regions based on geography, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and the Middle East & Africa. North America is anticipated to hold the largest share in the Anorexiants market due to a rise in the prevalence of obesity and the high adoption of new drugs.

Moreover, the increase in healthcare facilities and advancements in technologies have significantly contributed to the Anorexiants market. Europe is expected to make a significant contribution to the Anorexiants market due to an increase in the launch of new drugs and easy approval of drugs, leading to growth in the market.

Anorexiants Market: Key Players

Some of the key players present across the value chain of the global Anorexiants market are Akrimax Pharmaceuticals, LLC, Teva Pharmaceuticals, Janssen Ortho, LLC, Roche Pharmaceuticals, Arena Pharmaceuticals GmbH, Novo Nordisk A/S, Abbott Pharmaceuticals PR Ltd., Epic Pharma, LLC. Patheon Pharmaceuticals Inc. Catalent Pharma Solutions, LLC, Recordati Rare Diseases Inc., MOVA Pharmaceuticals.

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/9574

Key Segments Profiled in the Anorexiants Market Survey

By Drug Class:

• Catecholaminesb
• Serotoninb

By Route of Administration:

• Oral
• Subcutaneous

By End User:

• Institutional sales
• Hospitals
• Clinics
• Retail sales
• Online pharmacies
• Mail Order Pharmacies

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs